Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-EGFR/CD3 bispecific antibody SMET12

A bispecific antibody and T-cell engager (TCE) targeting both the tumor-associated antigen (TAA) human epidermal growth factor receptor (EGFR) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-EGFR/CD3 bispecific antibody SMET12 binds to both CD3 expressed on T cells and EGFR expressed on tumor cells. This crosslinks cytotoxic T lymphocytes (CTLs) and EGFR-expressing tumor cells, and activates and redirects CTLs to EGFR-expressing tumor cells. This leads to CTL-mediated killing of EGFR-expressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.
Synonym:anti-CD3/anti-EGFR bispecific antibody SMET12
anti-EGFR/anti-CD3 bispecific antibody SMET12
EGFR x CD3 bispecific antibody SMET12
EGFR x CD3 T-cell engager SMET12
EGFR x CD3 TCE SMET12
Code name:SMET 12
SMET-12
SMET12
Search NCI's Drug Dictionary